APLT
Price
$0.40
Change
-$0.00 (-0.00%)
Updated
Apr 25 closing price
Capitalization
56.39M
12 days until earnings call
EDIT
Price
$1.54
Change
-$0.07 (-4.35%)
Updated
Apr 25 closing price
Capitalization
128.91M
4 days until earnings call
Ad is loading...

APLT vs EDIT

Header iconAPLT vs EDIT Comparison
Open Charts APLT vs EDITBanner chart's image
Applied Therapeutics
Price$0.40
Change-$0.00 (-0.00%)
Volume$1.38M
Capitalization56.39M
Editas Medicine
Price$1.54
Change-$0.07 (-4.35%)
Volume$1.08M
Capitalization128.91M
APLT vs EDIT Comparison Chart
Loading...
APLT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APLT vs. EDIT commentary
Apr 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLT is a StrongBuy and EDIT is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 26, 2025
Stock price -- (APLT: $0.40 vs. EDIT: $1.54)
Brand notoriety: APLT and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLT: 64% vs. EDIT: 26%
Market capitalization -- APLT: $56.39M vs. EDIT: $128.91M
APLT [@Biotechnology] is valued at $56.39M. EDIT’s [@Biotechnology] market capitalization is $128.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $276.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLT’s FA Score shows that 0 FA rating(s) are green whileEDIT’s FA Score has 1 green FA rating(s).

  • APLT’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 1 green, 4 red.
According to our system of comparison, EDIT is a better buy in the long-term than APLT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLT’s TA Score shows that 5 TA indicator(s) are bullish while EDIT’s TA Score has 4 bullish TA indicator(s).

  • APLT’s TA Score: 5 bullish, 4 bearish.
  • EDIT’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, APLT is a better buy in the short-term than EDIT.

Price Growth

APLT (@Biotechnology) experienced а +19.73% price change this week, while EDIT (@Biotechnology) price change was +20.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.19%. For the same industry, the average monthly price growth was -3.08%, and the average quarterly price growth was -10.41%.

Reported Earning Dates

APLT is expected to report earnings on Aug 07, 2025.

EDIT is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+8.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EDIT($129M) has a higher market cap than APLT($56.4M). EDIT YTD gains are higher at: 21.260 vs. APLT (-53.434). APLT has higher annual earnings (EBITDA): -91.93M vs. EDIT (-233.11M). EDIT has more cash in the bank: 270M vs. APLT (98.9M). APLT has less debt than EDIT: APLT (1.97M) vs EDIT (35M). EDIT has higher revenues than APLT: EDIT (32.3M) vs APLT (-212K).
APLTEDITAPLT / EDIT
Capitalization56.4M129M44%
EBITDA-91.93M-233.11M39%
Gain YTD-53.43421.260-251%
P/E RatioN/AN/A-
Revenue-212K32.3M-1%
Total Cash98.9M270M37%
Total Debt1.97M35M6%
FUNDAMENTALS RATINGS
APLT vs EDIT: Fundamental Ratings
APLT
EDIT
OUTLOOK RATING
1..100
1919
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
23
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9995
PRICE GROWTH RATING
1..100
9656
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
42n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (23) in the Biotechnology industry is in the same range as APLT (49) in the null industry. This means that EDIT’s stock grew similarly to APLT’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as APLT (100) in the null industry. This means that EDIT’s stock grew similarly to APLT’s over the last 12 months.

EDIT's SMR Rating (95) in the Biotechnology industry is in the same range as APLT (99) in the null industry. This means that EDIT’s stock grew similarly to APLT’s over the last 12 months.

EDIT's Price Growth Rating (56) in the Biotechnology industry is somewhat better than the same rating for APLT (96) in the null industry. This means that EDIT’s stock grew somewhat faster than APLT’s over the last 12 months.

EDIT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as APLT (100) in the null industry. This means that EDIT’s stock grew similarly to APLT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLTEDIT
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
80%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 5 days ago
77%
Declines
ODDS (%)
Bearish Trend 11 days ago
88%
Bearish Trend 19 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
APLT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IIIAX12.04N/A
N/A
Voya International Index Port A
ABWYX15.13N/A
N/A
AB All Market Total Return Advisor
MSEEX23.35N/A
N/A
Morgan Stanley Europe Opportunity C
GQEPX21.32N/A
N/A
GQG Partners US Select Quality Eq Inv
GEMNX23.62N/A
N/A
GMO Emerging Markets R6

APLT and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLT has been loosely correlated with AMGXF. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if APLT jumps, then AMGXF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLT
1D Price
Change %
APLT100%
+0.10%
AMGXF - APLT
33%
Loosely correlated
N/A
TNFA - APLT
28%
Poorly correlated
+14.58%
COEP - APLT
27%
Poorly correlated
-38.25%
BPMC - APLT
27%
Poorly correlated
+1.82%
EDIT - APLT
25%
Poorly correlated
-4.35%
More